Please select your page
  • Slide
  • Slide
  • Slide

Audit committee

CERENIS christian chavyChristian Chavy
President of the Audit committee, Chief Executive Officer of Stallergenes

Christian Chavy brings substantial pharma and biotech management experience to the Board. He is currently Chief Executive Officer of Stallergenes. In 2010, Mr. Chavy joined ARES Life Science, an investment fund dedicated to healthcare. Previously, he served as President of Global Operations for Actelion Pharmaceuticals. Prior to joining Actelion, he was Vice President at Serono’s reproductive medicine strategic unit in Geneva and Chairman of Serono’s French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France.


CERENIS Richard PASTERNAKRichard Pasternak, M.D.
Member of the Audit committee, Chairman

Dr. Pasternak has had a long-standing research interest in lipid disorders and atherosclerosis, as well as patterns of practice and disease management and prevention. Previously, he was Vice President, Head of Cardiovascular Clinical Research and Head of Global Scientific Affairs and Scientific Leadership at Merck & Co from 2004 and 2010. Prior to this, he was Director of Preventive Cardiology and Cardiac Rehabilitation at Massachusetts General Hospital from 1992 to 2004, and he was Associate Professor of Medicine at the Harvard Medical School.
Dr. Pasternak has authored more than 100 publications and has spoken widely on the development of drugs for the treatment of cardiovascular diseases, and about how academia and industry can better collaborate in biomedical research. He is currently a faculty member of the Weill Cornell School of Medicine, and serves on the Boards of the Founder’s Affiliate of the American Heart Association, the Galien Foundation, and Essentialis Therapeutics.



B.Yanni 10 14sq

Barbara Yanni, JD, MA, BA
Member of the Audit committee, Independent Administrator 

Barbara is currently an Independent Director of three other clinical-stage biotech companies: Trevena Inc. (NASDAQ: TRVN), Vaccinex, Inc. and Symic Bio. She has more than thirty years of experience in pharma and biotechnology. As Chief Licensing Officer at Merck & Co., Inc. she has built strong relationships within the pharmaceutical, biotech and venture community. She oversaw successful strategic collaborations for 33 clinical and/or commercial compounds, 13 preclinical compounds and more than 100 compounds at the discovery, formulation or research technology stage. Prior to her leadership roles in business development at Merck, Barbara conducted financial analyses of business development opportunities and employee benefits and devised and implemented strategies to minimize Merck’s corporate taxes.

Barbara Yanni holds an AB in Physics from Wellesley College, an LLM in Taxation from New York University and a JD from Stanford Law School.



Cerenis Therapeutics Holding SA
33-43 av. Georges Pompidou – Bât. D2
31130 Balma – France
Tel. +33 5 62 24 97 06
Fax +33 5 61 57 34 12


Cerenis Therapeutics Inc
PO Box 861
Lakeland, MI 48143